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Abstract 
Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by immune-
mediated destruction of insulin-producing beta-cells in the pancreas. It is the most 
common metabolic disease in the young, with incidence in childhood increasing steadily. 
T1DM is associated with dramatically increased mortality and morbidity, and is 
accompanied by enormous costs. All this clearly indicates that despite continuous 
improvements in the use of exogenous insulin, current T1DM therapeutic strategies are 
far from being fully satisfactory. An interesting alternative to insulin administration is 
represented by the transplantation of isolated islets, which has the advantage of 
restoring the lost beta-cell mass and re-establish the feedback between glycemic values 
and insulin release. However, the mandatory use of immunosuppressive agents, with 
their unavoidable adverse effects, remains one of the major limitations to a wider use of 
islet transplantation. This problem could be overcome if isolated islets are coated with 
materials able to protect the cells from immunological attacks while allowing normal cell 
nutrition and oxygenation. In addition, the use of appropriate anti-inflammatory 
molecules during islet transplantation and the possibility of tracking and homing the graft 
could represent major advances in the field. With all this in mind, in this doctoral project 
the candidate has explored the use of nanomedicine tools to evaluate the role of 
multilayer nanoencapsulation, anti-inflammatory nanostructures, and selective 
nanoparticle-guided homing in human islet transplantation for the treatment of T1DM. 
The main objectives pursued and reached during the course have been a) the 
development of a system to immunoprotect isolated human islets by a novel multi-layer-
by-layer nanocoating system, with maintenance of in-vitro viability and function; b) the 
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evaluation of whether nanocoated human islets could cure chemically induced diabetes 
in mice; c) the assessment of the effects of anti-inflammatory nanomolecules on human 
islet properties; and d) the feasibility of tracking and transplanting human islets into 
laboratory animals using nanoparticle-guided homing. The overall results support the 
potential of the nanomedicine systems developed during this doctorate course for 
implementation in the human clinical setting. 
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INTRODUCTION 
Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by immune-
mediated destruction of insulin-producing beta-cells in the pancreas1. It is the most 
common metabolic disease in the young, with incidence in childhood, increasing at 
about 3% per year (equivalent to a doubling time of 20-25 years)1-3. In addition, 30 to 
50% new cases of T1DM develop after 30 years of age3-5. Finally, 5-10% of patients 
originally diagnosed as having type 2 diabetes (T2DM) are affected by a less severe 
and more slowly progressing form of T1DM, usually referred to as “Latent Autoimmune 
Diabetes of Adults” (LADA)5. Collectively, about thirty million people world-wide and two 
million people in Europe suffer from this disease1-5. In Italy, it has been estimated that 
there are more than 100,000 type 1 diabetic patients, of whom approximately 2,000 in 
Tuscany2,6. On top of all this, a dramatic burden is associated with T1DM, including a 2 
to 4 fold higher mortality rate and the development of macro- and microvascular 
complications1-5. As a matter of fact, although recent studies have shown that intensive 
insulin treatment can reduce the onset and progression of diabetic complication in 
T1DM, nevertheless diabetic nephropathy still occurs in 20–30% of patients 
(representing the single leading cause of end-stage renal disease) and retinopathy can 
affect up to 90% of patients (resulting the most frequent cause of new cases of 
blindness among adults aged 20–74 years); in addition, diabetic neuropathies are 
known to affect 50% of patients after 20 yrs of diabetes. Unsurprisingly, this is 
accompanied by enormous costs. In the U.S., the national economic burden of diabetes 
in its several forms reached $218 billion in 2007 7. This estimate includes $153 billion in 
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higher medical costs and $65 billion in reduced productivity, with an average annual 
medical cost per T1DM case of  $14,856.  As calculated in certain areas of Italy, costs 
per person per year are € 830 in diabetic patients and € 182 in non-diabetic individuals8. 
Diabetes treatment accounts for 18.5% of the total cost, and the excess of expenditure 
is particularly high in T1DM (rate ratio 7.7 vs non-diabetic individuals). In addition, 
diabetes is associated with  increased costs due to  treatment with several other drug 
categories, including ACE inhibitors, anti-thrombotic drugs and statins. Finally, costs 
increase dramatically in the case of chronic complications. In Italy, yearly cost of non-
fatal myocardial infarction is € 2,297, of non-fatal stroke €  6,583, of end-stage renal 
disease €  43,075-56,717, and of lower extremity amputation € 10,177 9.  
Clearly, this scenario indicates that despite continuous improvements in the use of 
exogenous insulin, current T1DM therapeutic strategies are far from being fully 
satisfactory. Exogenous insulin needs to be administered several times per day, and 
even with modern insulin analogues the normally feed-back regulated insulin secretion 
cannot be mimicked. More scaringly, treatment with exogenous insulin is associated 
with high risk of acute hypoglycemic complications, which may be even life 
threatening10. In intensively treated patients, the overall rate of severe hypoglycemia is 
higher than one episode/patient-year and episodes are  reported by approximately one 
third of subjects11. These events may in some cases may have severe consequences, 
including car accidents12.   
Strategies alternative to insulin administration are represented by whole pancreas or 
isolated islet transplantation, which have the advantage of restoring (at least in part) the 
lost beta-cell mass and re-establish the feedback between glycemic values and insulin 
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release13,14. The first case of a whole pancreas transplantation was reported in 1966 at 
the University of Minnesota, (Minneapolis, MN, USA). Since then, more than 40,000 
pancreas transplants have been reported to the International Pancreas Transplant 
Registry. A simultaneous pancreas and kidney transplant (SPK), usually with both 
organs from the same deceased donor, is the most common transplant involving the 
pancreas, but it can also be done with a pancreas from a deceased donor and a kidney 
from a living donor, or both organs (segmental pancreas) from a living donor. The other 
categories are pancreas after kidney transplantation (PAK) and pancreas transplant 
alone (PTA). Currently, pancreas half-life is around 12 years in SPK and around 8 years 
in PAK and PTA15. In addition, SPK patients have a better life expectancy than those in 
the waiting list or receiving a kidney from deceased donor13. The advantages of this 
surgical procedure have to be balanced against the potential mortality and morbidity 
associated with it, and the side-effects from the long-term anti-rejection therapy that is 
needed to prevent alloimmunity and autoimmune recurrence of diabetes. Perioperative 
mortality is around 3%, and relaparotomy is required in about 20% of cases13,15. Risk of 
infection (in particular early after grafting) and cancer (including lymphoproliferative 
disease) is also increased, due to the generalized immunosuppression13.  
Isolated islet transplantation has the potential advantage of transplanting only small 
amounts of tissue, which can be done with reduced surgical risk to the patients. The first 
successful series was reported in 1990 in surgical diabetes, while the results in T1DM 
slowly improved during the 1990s until 1999, when insulin independence was reported 
in seven out of seven consecutive T1DM patients treated with islet transplantation using 
a glucocorticoid-free immunosuppressive regimen16. Since this report, clinical islet 
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transplantation activity has dramatically increased all over the world. A multi-center trial 
to evaluate the reproducibility of the Edmonton study organized by the Immune 
Tolerance Network reported variable rates of success, indicating that the complexity of 
the procedure should not be underestimated 17. In the centers with the most experience, 
approximately 80% of patients treated with islet transplantation could achieve insulin 
independence within the first year post-transplantation17. A major problem in current 
islet transplantation is the progressive loss of insulin independence over time. However, 
recent reports from Edmonton suggest that 83% of patients show islet function 
assessed by C-peptide secretion at 5 years18. Furthermore, hypoglycemia was 
prevented even when exogenous insulin was required to maintain glycemic control, and 
the HbA1c level was well controlled in those back on insulin but C-peptide positive. The 
effects on the prevention of hypoglycemia can persist as long as the residual islet 
function is retained16-18.  
Despite these encouraging results, the mandatory use of immunosuppressive agents, 
with their unavoidable adverse effects, is one of the major limitations to a wider use of 
islet transplantation. This problem could be overcome if isolated islets are coated with 
materials able to protect the cells from immunological attacks while allowing normal cell 
nutrition and oxygenation. Another important issue is the choice of transplantation site. 
Islet implantation into the liver through the portal vein is the current clinical practice 16-18. 
However, it has now been recognized that this implantation site has several 
characteristics that can hamper islet engraftment and survival, such as low oxygen 
tension, an active innate immune system, and the provocation of an inflammatory 
response19. Therefore, transplantation of isolated islets is an attractive option in the 
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treatment of T1DM patients, but current applications are limited by several constraints. 
In conclusion, type 1 diabetes is a common disease, with continuously increasing 
incidence and prevalence, and associated with dramatic personal and social burden. 
Improved T1DM therapy/cure strategies are highly needed, able to safely re-establish 
regulated endogenous insulin secretion, which is not currently available with exogenous 
insulin and current transplantation procedures.  
A path to this might be the use of isolated islet transplantation, as long as 
immunosuppression is avoided and implantation site optimized. To overcome the 
problem of the use of immunosuppression, microencapsulation of the islets has been 
evaluated 20,21. Microencapsulation in the field of pancreatic islets means entrapment in 
high-viscose ultrapure alginate droplets stabilized with divalent positively charged ions 
such as, e.g., barium or calcium. First developed a few decades ago, this approach has 
been successful in laboratory animals and occasionally so also in large mammals 22. A 
few attempts to implement microencapsulated islet transplantation for human treatment 
have generated elusive results 23. A major problem with this approach   is represented 
by the unfavorable ratio between encapsulated cell volume and overall capsule volume, 
which causes sluggish insulin release and only allows transplantation subcutaneously or 
intraperitoneally. In addition, the porosity of the system does not completely prevent the 
passage of molecules involved in inflammatory and fibrotic reactions. A potential 
solution to all these problems is represented by the use of nanosized, polyelectrolyte 
multilayers to coat isolated islets. A method to deposit nanomultilayers onto isolated 
islets is the layer-by-layer procedure described recently 24, that allows, under given 
circumstances, good islet cell survival and function. The technique is based on the 
 
 
6 
 
 
attachment of highly and oppositely charged polyions onto charged surfaces in a self-
assembly process. By such method, complete coverage of the islets can be achieved 
because the perinsular capsule serves as a template for polyion adhesion. Moreover, a 
system based on electrostatic interactions of oppositely charged polymers can be 
tailored to support lower layer islet functionality and perhaps fibrosis reduction in the 
outermost layer. Some other advantages of the multilayer technology are the nanometer 
thickness of the coating allowing for faster response to glucose level changes, and to 
provide multifunctionality like to improve homing of the islets, reduced immunogenicity 
or the possibility to dope the polymer matrix with factors to prevent immunological 
insults. This latter goal could also be achieved by nanoparticles with specific anti-
inflammatory properties, such as Zinc Oxide nanoparticles (ZnO NPs). As a matter of 
facts, the potential utility of ZnO NPs in the treatment of autoimmunity disease has been 
recently suggested 25. The data of the authors demonstrate that ZnO NPs can induce 
toxicity in a cell-specific and proliferation-dependent manner. In particular, it was shown 
that ZnO NPs exhibit a strong preferential ability to kill cancerous T cells (28-35x) 
compared to normal cells. Mechanisms of toxicity appear to involve the generation of 
reactive oxygen species (ROS), with cancerous T cells producing higher inducible levels 
than normal T cells. 
As for the problem with transplantation site, alternative anatomical locations that may 
offer maximum engraftment, efficacious use of produced insulin, and maximum patient 
safety are being proposed, such as subcutaneous transplantation, which guarantees 
maximum patient safety, and the omentum, which offers drainage of produced insulin 
into the portal vein for direct utilization in the liver. In these regards, it is of interest the 
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possibility of guiding the implanted islets towards a predetermined implantation site. In 
particular, preliminary studies have demonstrated that mammalian cells pre-treated with 
magnetic nanoparticles (MNPs) can be easily controlled and localized to the target site 
by using low intensity magnetic fields 26. Specifically, when mammalian cells are 
cultured in a medium containing the MNPs, they interact with the particles, internalize 
them, and become “magnetized” and thus able to respond to an external magnetic field. 
This approach should therefore allow the site-specific, guided localization of the MNP-
cells.  
With this scenario in mind, in this doctoral project we have explored the use of 
nanomedicine tools to evaluate the role of multilayer nanoencapsulation, anti-
inflammatory nanostructures, and selective nanoparticle-guided homing in human islet 
transplantation for the treatment of type 1 diabetes. Pros and cons of the research have 
been considered since the beginning, and are summarized in table 1. For example, 
whereas the candidate was confident that multilayer encapsulation can lead to the 
development of bioartificial systems with reliable in-vitro function, the achievement of a 
proper function may be not an easy task to reach in animal models. In addition, the 
possibility of using anti-inflammatory particles as an add-on approach to multilayer 
coating to promote graft acceptance has never been tested before, and although 
technically feasible, it is not known how the islet cells will react to these steps. 
Nevertheless, for each given experiment had several checkpoints, including in-depth 
morphological, functional examinations, even in case of not successful steps it would 
have been possible to evaluate the mechanisms involved and possibly proceed with 
properly modified experimental approaches. 
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Table 1: Some innovations and risk factors of this doctoral project  
Main task Innovation grade Uncertainty grade Comment 
Human islet 
isolation 
Relatively high Low  Only few 
laboratories in the 
world successful in 
human islet 
preparation 
Multilayer nano 
coating 
Relatively high Relatively low Multilayer coating 
of human islets 
previously 
reported in only 
one study; several 
new chemicals 
testable 
ZnO NP addition High High  Novel approach 
with human islets 
Use of magnetic 
nanoparticles 
Very high High  Novel approach 
with human islets 
Transplantation 
steps   
Relatively high Relatively high The use of islets 
modified as 
proposed is highly 
innovative in 
transplantation  
Quality control 
(morphology, 
molecular biology) 
Relatively high Very low The used 
methodologies are 
well known, but 
here applied to 
new fields 
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In summary, this doctoral project had three main primary objectives (PO): 1) to develop 
a system to immunoprotect isolated human islets by novel multilayer Nanosystems, with 
maintenance of in-vitro viability and function; 2) to cure chemically induced diabetes in 
laboratory animals by transplantation of human islets immunoprotected by multilayers 
and 3) to test the feasibility of transplanting immunoprotected human islets into 
laboratory animals using nanoparticle-guided homing. 
In addition, several interim objectives have been pursued, which include: a) 
development of new nanosystems for isolated islets coating; b) application to human 
islets of nanoparticles for protection from immune attack; c) application to human islets 
of magnetic nanostructures for guided homing; d) combination of the techniques 
described in a) to c); e) transplantation of human islets treated as in a) to c) into non-
diabetic laboratory animals. The overall design is reported in figure1. 
 
Figure 1: Overall design and different goals of the doctorate project  
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MATERIALS AND METHODS 
Isolation and culture of human islets 
Human islets were isolated from 61 non-diabetic cadaveric organ donors (age: 65±16 
yrs, body mass index (BMI): 25.87 ± 3.49 kg/m2, mean glycemia: 153 ± 43), with 
approval of the local ethical committee by using the protocol which was developed in 
our laboratory with little modification27-30, schematically reported in figure 2. 
 
 
Figure 2: Schematic representation of the different steps involved in the isolation of human pancreatic 
islets. 
 
Briefly, the gland was trimmed by careful dissection of the surrounding fat tissue, lymph 
nodes, and vessels to be divided into two portions: the head and the body with the tail. 
The latter portion was used for islet preparation. The pancreatic duct was cannulated 
with a 18-gauge angiocatheter and 200 ml of Hank’s solution (HBSS), completed with 
10% Adult bovine serum and 3 mg/ml collagenase P (Roche Diagnostics) was injected 
into the pancreatic duct until it completely distended the gland. Then, the pancreas was 
placed into a sterile glass beaker  in a water bath (37°C/12 to 15 minutes). 
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Successively, the gland was gently hand-shaken at room temperature until free islets 
were observed in a sample. At this point, the digestate was sequentially passed through 
300-µm and 90-µm mesh stainless steel filters. The resulting suspension and the tissue 
trapped on the 300-µm mesh filter were placed back into the beaker with HBSS for 
further digestion. The tissue remaining on the 90-µm filter was washed with HBSS 
supplement with10% of adult bovine serum (ABS). The same procedures of filtration, 
washing, and settling in the HBSS solution was repeated at 5- to 8-minute intervals up 
to 40 minutes. For the purification, the digested suspension was aliquoted in to 50-mL 
Falcon conical tubes and centrifuged at 1000 rpm for 2 minutes. The supernatant was 
discarded and the pellet suspended in 15 ml of a solution containing Lymphoprep:HBSS 
(with 10% adult bovine serum) with different ratio (for example 80:20 or 70:30). Then 10 
ml of HBSS was layered over the Lymphoprep-HBSS solution. The tubes were 
centrifuged at 1800 rpm for 5 minutes at 4°C. Islets recovered from the interface 
between the two layers were again centrifuged at 1800 rpm for 2 minutes, following 
which the supernatant was discarded and the islet pellets were aliquoted into 75-cm2 
suspension flasks containing M199 medium containing 5.5 mM glucose, 10% bovine 
serum (GIBCO, Lifescience Technologies, Paisley, UK), 100 UI/L penicillin, 100 mg/L of 
streptomycin, 750 µg/L amphotericin and 50 mg/L gentamycin. The islet yield was 
evaluated by staining a sample with dithizone (DTH). The islet number was counted to 
express the total yield as the equivalent of 150 µm sized islets (IE). The purity of the 
islets was calculated as the ratio between DTH-stained and total (stained and 
unstained) cell clusters 31. 
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INS-1E beta cells 
Rat clonal insulinoma INS-1E beta cells (a gift from prof. C. Wollheim, Geneva) were 
cultured in normal RPMI 1640 medium (Invitrogen, Paisely, UK) supplemented with L-
glutamine, 10% fetal bovine serum, 1 mM sodium pyruvate with beta mercaptoethanol, 
10 mM HEPES, 100 U/ml penicillin and 100 µg/ml streptomycin at 37 °C in a humidified 
incubator.  
 
Isolation of PBMCs  
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats of healthy 
blood donors using density gradient centrifugation. Briefly, 10 ml of Ficoll–Hypaque 
(Sigma, St. Louis, MO) was stratified under 20 ml of peripheral blood and centrifugation 
was performed at 400 × g for 20 min at room temperature. Recovered PBMCs were 
washed three times with D-PBS and assessed for viability using trypan blue (Molecular 
Probes®, USA) staining and counted using automated countess™ (Invitrogen). The 
cells were  resuspended at a final concentration of 1x106 cells/ml in RPMI-1640 (gibco, 
USA), containing 10% fetal bovine serum (FBS),10 mM HEPES, 100 U/ml penicillin and 
100 µg/ml streptomycin and cultured at 37ºC with 5% CO2. 
 
Multilayer nanoencapsulation 
Layer-by-layer nano-encapsulation was performed by electrostatic binding of differently 
charged polymers. Chitosan [(Poly(D-glucosamine) deacetylated chitin)] (figure 3) and 
PSS [(Poly(styrenesulfonic acid sodium salt)] (Figure 3) (Sigma Aldrich Co, St. Louis, 
MO, USA) were dissolved (1 mg/ml) in medium M199 and stored at 37oC for 
approximately 48 hrs before the nano-encapsulation procedure. Chitosan has been 
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used as polymer for the first layer in contact with the islets, since it has a very low 
positively charged zeta potential and therefore it can able to interact with the perinsular 
capsule of the cell serves as a template for the adhesion. Also, chitosan was used in the 
outermost layer, to allow better interaction with the surrounding microenvironment 32, 33. 
Briefly, the islets were kept in the medium containing chitosan for 15 min, followed by 3 
min of washing to remove the unbound compound; then, the chitosan coated islets were 
incubated with medium containing PSS for 15 min followed by 3 min washing. This 
procedure was repeated to obtain nine layers by alternate binding of the oppositely 
charged polymers (figure 4). At the end, the nanocoated islets were washed and 
incubated in supplemented medium M199  for quality control as well as in-vitro and in-
vivo work (see below).  
 
 
Figure 3: Chitin is the second most abundant natural polymer in the world after cellulose. Upon 
deacetylation, it yields the biomaterial Chitosan; Polystyrene sulfonic acid is a polymer 
and ionomer based on polystyrene. The polyanion is a white or off-white powder, readily soluble in water, 
and insoluble in lower alcohols.  
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Figure 4: Schematic representation of the layer-by-layer nanoencapsulation of human pancreatic islets by 
deposition of differently charged polymer multilayers on individual islet surfaces. Blue lines represent 
Chitosan; red lines represent PSS.  
 
To study the possible protective effects of nano-encapsulation in-vitro, islets were 
cultured in the presence of Interleukin-1beta (50U/ml, Roche) and Interferon gamma 
(1000U/ml, Roche)  for 72 hrs, or palmitate (0.5 mmol/L, Sigma Aldrich, St Louis, MO, 
USA) for 48 hrs. In such cases, we used metabolic labeling to study palmitate uptake by 
the cells. To do so, human islets were cultured on suspension culture dish in M199 
medium, supplemented with 5% (w/v) solution of FFA-free bovine serum albumin (BSA), 
prepared in serum-free M199 medium, 100 UI/L penicillin, 100 mg/L of streptomycin, 
750 µg/L amphotericin and 50 mg/L gentamycin. Islets were then treated with 100 µM 
palmitic acid-azide from  50 mM stock solution in DMSO and the same volume of 
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DMSO was used for the negative control. After 6-8 hrs of labeling at 37ºC in an 
incubator with 5% CO2, the islets were then washed twice with PBS containing 2% BSA. 
The cells were again resuspended in 500µl of click-iT reaction buffer mixture (440µl of  
click-iT buffer, 10 µl of 100mM CuSO4 and 50 µl of 1mg/mL of Alexa fluor 594 alkyne ) 
for 30 minutes in the absence of light. The cells were washed again with PBS containing 
2% BSA for 5 minutes and the cells were visualized using fluorescence microscopy. 
Some islets were fixed with 4% formalin for 1 hour and paraffin embedded, cross 
sections of 2µM thickness were made to study the localization of fluorescence molecule. 
For quantitative assessment, around 75-100 islets were handpicked and placed into an 
96 well plate, with the relative fluorescence intensity measured using a fluorescence 
spectrophotometer (FLUOstar Omega, BMG labtech, Germany). 
 
Preparation of zinc oxide nanoparticles 
To pursue the aim of using beta cell protective molecules, zinc oxide nanoparticles 
(ZnO NP) (Nanostructured and Amorphous Materials Inc, Houston, TX) were used 34. 
They were dispersed at a concentration of 100 ug/ml in arabic gum 5% (51200 Sigma-
Aldrich) and the pH adjusted at 7. The dispersion was vortexed for five minutes and 
sonicated overnight in a 20 W sonication bath (AGE Electronica SRL, Italy). The mixture 
was then ultracentrifuged at 50000 g for 30 minutes at room temperature and particles 
were risuspended in arabic gum 5% at a concentration of 400 ug/ml. The concentration 
of the nanoparticles was further confirmed by spectrophotometric analysis at the 
wavelength of 380 nm after calibration34. These as-produced nanoparticles range 
between 90 mm and 200 nm in size. In addition, Zn intracellular detection was 
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accomplished by a commercial kit (BioVision, USA), according to manufacturer’s 
instructions. BioVision's Zinc Assay Kit is a colorimetric assay in which Zinc binds to a 
ligand with the development of absorbance at 560 nm. The assay has a detection 
sensitivity 0.2 μg/ml (~1-3 μM). 
 
Preparation of multiwalled carbon nanotubes (MWCNTs) 
MWCNTs were used for tracking and homing of isolated islets. MWCNTs were provided 
by Nanothinx SA, Rio Patras, Greece; these MWCNTs have been previously 
characterized using scanning electron microscopy (SEM), Raman spectroscopy, 
transmission electron microscopy (TEM), thermogravimetric analysis (TGA) and 
focused electron microscopy 35. The carbon content of the as-produced product is 
97.06%, and the amount of amorphous carbon is <1%. Al and Fe are the main metal 
impurities; the catalyst used in the production of the tubes is Fe-based, and the support 
is alumina. The content determined using the ICP analysis (inductively coupled plasma 
mass spectrometry) showed a Fe/Al ratio of 7 ± 1 (w/w). A water dispersion of MWCNTs 
was achieved using pluronic F127 (PF127), a polyoxyethylene–polyoxypropylene block 
copolymer surfactant (Sigma-Aldrich, St. Louis, MO), dispersed in PBS 1X (Sigma) at 
0.1% concentration36. Briefly, MWCNTs were added (0.4 mgml−1), and the resulting 
mixture was sonicated using a Branson sonicator 2510 (Bransonic, CT, USA) at 20 W. 
The mixture was then centrifuged at 900 g for 10 min to remove residual nonsuspended 
nanotubes and any impurities. The concentration of the MWCNT solution, measured by 
spectrophotometric analysis, was 100 μg ml−1. A solution of singly dispersed nanotubes 
with uniform length (approximately 2 ± 0.5 μm) was found 35. 
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As control compound we used Endorem®, a paramagnetic contrast agent 37 consisting 
of ferumoxide nanoparticles coated with dextran, measuring 50 to 180 nm. Endorem® 
was obtained from AMAG Pharmaceuticals Inc. (Guerbet S.A., France) in water at a 
concentration of 11.2 mg/ml Fe.  
 
Cell viability 
Cell viability was assessed by several techniques, depending on the given experimental 
setting. In some cases, it was assessed by staining the islets with Hoechst 33342 and 
propidium iodide (PI). Briefly, on the day of determination, the islets were hand picked 
(15 islets/condition) and incubated with fresh culture medium containing Hoechst 33342 
(20 µg/ml /ml) and PI (10 µg/ml); after incubation of the cells for 15 minutes at 37ºC in 
the dark, the viability was assessed using a fluorescence microscope (Carl Zeiss, 
Oberkochen, Germany). The live/dead cells were analyzed using Image J software  
(NIH, Bethesda, Maryland, USA). 
Dimethylthiazol-2-yl) -2,5-Diphenyltetrazolium Bromide (MTT) assay was used to 
determine the effect of zinc oxide nanoparticles on cell viability. Briefly, INS-1E beta 
cells with a concentration of 20 × 103 cells/well were seeded into a 96-well plate and 
cultured for 2 days with RPMI culture medium. The culture medium was then replaced 
with fresh medium containing zinc oxide nanoparticles. After incubation, the 
nanoparticle-modified medium was replaced with 100 μL KRBH buffer solution 
containing 0.1% of BSA and incubated for 40 minutes at 37ºC and 5% CO2. The KRBH 
buffer was again replaced with 100 µl of KRBH containing 11.1 mM of glucose and 0.5 
mg/ml of MTT and incubated for another 90 minutes at 37ºC  with 5% of CO2. The 
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KRBH buffer solution containing MTT was then replaced with 100 μL of 
dimethylsulfoxide (Sigma) and left for 20 minutes on a platform shaker to solubilize the 
converted formazan. The absorbance was measured on a FLUOstar omega microplate 
reader (BMG Labtech, Germany) at a wavelength of 570 nm with background 
subtracted at 690 nm 38. 
The viability of PBMCs was measured on trypan blue 0.4% (10 µl) stained samples. 
Cells were counted with a plastic disposable Countess® Cell Counting Chamber 
(Invitrogen) using automated Countess® reader and the data interpreted accordingly. 
To evaluate the cellular effects of ZNO NPs, INS-1E cells (4x104 cells/cm2) were treated 
with Zinc oxide nanoparticle containing culture medium (5, 10, 25, 50 µg/ml). After 48 
hours of incubation, the culture medium was replaced with plain, fresh culture medium 
for up to 7 days to accomplish the studies described below. To investigate the dose 
dependent effect of ZnO nanoparticle on PBMCs, we cultured the PBMCs in a 96 well 
plate (1x105 cells/well) with RPMI culture medium and assessed cell viability after 12, 24 
and 48 hours of treatment. Finally, co-culture work was done with 6 well cell culture 
plates with cell culture inserts (Thermo Scientific Nunc®, DK-4000 Roskilde, Denmark). 
Briefly, 100 handpicked human islets were suspendedin RPMI medium (containing 10% 
bovine serum (GIBCO, Life science Technologies, and Paisley, UK), 100 UI/L penicillin, 
100 mg/L of streptomycin, 750 µg/L amphotericin and 50 mg/L gentamycin)  in an 
untreated 6 well plate followed by a cell culture insert containing a polycarbonate 
membrane with a pore size of 0.4µm was inserted; the PBMCs cells were then seeded 
in the cell culture insert with a concentration of 1x106 cells/well and cultured for  24 hrs. 
After 24 hrs of co-culture the human islets were assessed for insulin secretion studies. 
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Electron microscopy was used to assess cell viability and also morphometry as well as 
ultrastructure, using methods previously described 39, 40. Briefly, samples were ﬁxed with 
2.5 % glutaraldehyde in 0.1 mol/l phosphate buffer with pH 7.4 for 2 hrs at 4ºC. After 
rinsing in phosphate buffer, specimens were post-ﬁxed in 1.0 % phosphate-buffered 
osmium tetroxide for 30 min at 4ºC, then dehydrated in a graded series of ethanol, 
transferred to propylene oxide, and embedded in Poly/bed 812 (Poliscience, CA, USA). 
Ultrathin sections (60 to 80 nm thick) were obtained by using a diamond knife and 
sections were placed on copper grids (200 mesh), and stained with uranyl acetate and 
lead citrate. Micrographs were obtained with varying degrees of magniﬁcation, as 
appropriate40, 41.  
 
Labeling of INS-1E beta cells and human islets with MWCNTs  or Endorem®   
INS-1E cells (4x104 cells/cm2) and isolated human islets (approximately 100-300) were 
labeled using an Endorem® containing culture medium (10, 50, 100 or 200 µg/ml) or an 
MWCNT-containing culture medium (5, 15, 50 or 100 µg/ml). After 48 hours of 
incubation, the labeling medium was replaced with plain, fresh culture medium for up to 
15 days to accomplish the studies described below. 
Prussian blue/iron staining was used to study the uptake of Endorem® and MWCNTs in 
INS-1E cells. Briefly, the working solutions consisting of 4% (w/v) potassium 
ferrocyanide solution, 1.2 mM hydrochloric acid and 1% pararosaniline solution (w/v) in 
methanol, prepared according to the manufacturer’s (Accustain, Sigma-Aldrich, St. 
Louis, USA) protocol. Incubation with cells was performed at 37 °C for 2 hours. This 
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method induces a reduction that changes ferric iron to the ferrous state with the 
formation of a ferrocyanide precipitate, which is blue in color. 
 
In-vitro functional studies 
Insulin secretion studies with human islets were performed by the batch incubation or 
the perifusion technique, according to procedures previously developed 27,39,42. For the 
batch incubation experiments, human islets (15 islets for each point) were pre-incubated 
with Krebs Ringer Bicarbonate Solution (KRBS) containing 3.3 mmol/L glucose and 1% 
albumin for 45 min. Afterwards, islets were washed with 2 ml of KRBS and incubated 
again for 45 minutes with 3.3 mmol/L glucose, followed by 16.7 mM glucose KRBS for 
additional 45 minutes. The dynamics of insulin secretion were studied by using a multi-
channel perifusion system, equipped with a temperature controller. Approximately 50 
islets were loaded on Swinnex filter holders (Millipore, Cork, Ireland) containing 
nitrocellulose membranes, and perifused (flow rate: 0.2 ml/min) with KRBS containing 
3.3 mmol/l glucose for 20 min, 16.7 mmol/l glucose for 20 min, and again  3.3 mmol/l 
glucose for 15 min; in the final 6 min of perifusion, KRBS containing 30 mmol/l 
potassium chloride was used. The amount of insulin releases in the incubation solution  
was assessed by an insulin RIA kit (DIA Source Immunoassay S.A., Louvain-La-Neuve, 
Belgium). The collected solutions were measured for insulin content by using an insulin 
ELISA kit (Pantec) and the absorbance were read on FLUOstar omega plate reader 
(BMG Labtech, Germany). 
Insulin secretion studies were performed with the clonal cell line as well, according to 
previously developed procedures 27, 39, 42. Labeled and unlabeled INS-1E cells with a 
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concentration of 2x105 cells/ml were seeded onto poly D-lysine covered 24-well plates 
with standard culture conditions for 7 days. On the day of the secretion experiments, the 
culture medium was removed, and the cells were incubated with a glucose-free medium 
containing 1% FBS for 2 hours, which was then removed and replaced with a glucose-
free Krebs-Ringer bicarbonate solution (KRBS: NaCl 135 mM, KCl 3.6 mM, NaHCO3 5 
mM, MgCl2 0.5 mM, CaCl2 1.5 mM, NaH2PO4 0.5 mM, and HEPES 10 mM), containing 
0.1% BSA. After 30 min, the glucose-free KRBS was removed, and the cells were 
challenged with 3.3 mM glucose (basal) for 30 minutes, followed by incubation with 16.7 
mM glucose (stimulation) for 30 minutes. Insulin release was measured in triplicates 
using an ultrasensitive rat insulin ELISA kit (DRG Instruments GmbH, Marburg, 
Germany) according to the manufacturer's protocol. 
  
Transplantation studies 
Male C57BL/6J mice aged 8 weeks and weighing 20-25 g (Harlan Laboratories, Udine, 
Italy) were used as islet graft recipients. Recipient mice were made diabetic by the 
intraperitoneal injection of nicotinamide (150 mg/kg b.w.) (Sigma, Saint Louis, MO, 
USA), dissolved in saline, 15 min before administration of STZ (Sigma, 190 mg/kg b.w., 
i.p.), which was dissolved in buffer citrate (pH 4.5) immediately before use 43,44. Controls 
received both vehicles. Mice with a non-fasting blood glucose concentration of ≥ 200 
mg/100 ml were used as recipients. The experimental protocol followed the Principles of 
Laboratory Animal Care (US NH publication no. 83-85, revised 1985) and was approved 
by the Ethical Committee of the University of Pisa. 
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Mice were anesthetized with an intraperitoneal injection of 50 mg/kg b.w. penthobarbital 
sodium and transplanted with  approximately 500 islets under the kidney capsule, 
according to the procedures described by Zmuda et al. 45 and Zhi et al. 33. Briefly, a 
lumbar incision was made, the kidney exposed and the encapsulated and control 
human islets were placed underneath the kidney capsule using a Hamilton syringe.  
Blood glucose concentrations of recipient mice were monitored every 2 days. Fifteen 
days after transplant, we assessed the in vivo function of the transplanted islets by an 
intraperitoneal glucose tolerance test. Glucose (1.5 g/kg B.w., administered 
intraperitoneally as a 16.5 % solution) was given to 2-h fasted conscious mice. Blood 
samples were obtained sequentially from the tail vein before and after the glucose 
injection and immediately used for glucose determination by a glucometer or collected 
in EDTA-treated small tubes and centrifuged at 4°C (0-, 15- and 60-min samples), with 
storage of plasma at −20°C for subsequent insulin measurement. After the study period 
the kidneys bearing islet graft was harvested and assessed for various 
immunohistochemistry and EM analysis. 
 
In-vivo morphological evaluation of transplanted islets 
For immunohistochemistry determination of transplanted islet grafts, consecutive 
formalin fixed and  paraffin embedded tissue sections (2–4 μm thick) were dewaxed and 
subjected to immunostaining with the streptavidin–peroxidase technique, using the 
automated BenchMark XT staining system (Ventana Medical Systems, Tucson, 
Arizona, USA). Endocrine cells were identified by the anti-Chromogranin A (mouse 
monoclonal antibody, clone LK2H10, prediluted; Ventana Medical Systems), incubated 
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at 37°C for 20 min. Inflammatory cells were detected by the anti-CD45 (mouse 
monoclonal antibody, clone RP2/18, prediluted; Ventana Medical Systems), incubated 
at 37°C for 32 min; by the anti-CD68 (mouse monoclonal antibody, clone KP-1, 
prediluted; Ventana Medical Systems), incubated at 37°C for 26 min; by the anti-
myeloperroxidase (rabbit polyclonal antibody prediluted, Ventana Medical Systems), 
incubated at room temperature for 36 min. For each staining protocol microwave 
heating (in citrate buffer, pH 7.3) was used as pretreatment for antigen retrieval. To 
ensure antibody specificity, consecutive sections were incubated with isotype matched 
control immunoglobulins and in the absence of primary antibody. In these cases, no 
specific immunostaining was detected. 
Islets (both nano-encapsulated or uncoated) or the explanted graft-bearing kidneys 
were also studied by immunofluorescence. Samples were fixed with 4% (vol/vol) 
neutral-buffered formalin and later paraffin-embedded. The specimens were sectioned 
at a thickness of 2-4 µm. The paraffin sections were deparafinised and re-hydrated with 
xylene and a series of alcohol. The re-hydrated sections were stained with 
haematoxylin/eosin for  morphology studies. For double immunofluorescence staining,  
the deparafﬁnized samples were incubated overnight with anti-insulin, polyclonal guinea 
pig antibody (Life Technologies) at 1:100 dilution or anti-glucagon monoclonal mouse 
antibody (Sigma-Aldrich, St. Louis, MO, USA) at 1:3000 dilution; the following day the 
sections were kept at room temperature for 1 hour and washed with PBS containing 1% 
lamb serum, then the secondary antibodies, Alexa Fluor 594-conjugated AffiniPure 
donkey anti-guinea pig (Jackson ImmunoResearch) or anti-mouse (Jackson 
ImmunoResearch), for insulin and glucagon, respectively, were applied for one 
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additional hour at room temperature. Slides were rinsed in PBS and mounting medium 
with DAPI (Vector Laboratories, Burlingame, CA, USA) was applied over tissue sections 
for nuclear staining and covered with coverslip. For Immunohistrochemistry studies, 
images were acquired by a fluorescence microscope (Leica DM5500 B Leica 
Microsystems, Mannheim, Germany), and analyzed using the Leica MMAF software. 
For confocal laser scanning analysis, the Leica TCS SP8 microscope was used.   
Confocal images of 1.024 x 1.024 pixels were taken at 1 μm intervals through the z-axis 
of sections, by means of 20x non oil and 63x oil objective lenses. Z-stacks of serial 
optical planes were analyzed by confocal software (L.A.S. v4; Leica Microsystems, 
Cambridge, UK).  
 
In-vitro and in-vivo MRI imaging 
INS-1E beta cells ad human islets were labeled with Endorem® (50 µg/mL) or MWCNTs 
(15 µg/mL) and cultured in 5% CO2 incubator at 37 ºC. After 3, 7 and 15 days, the cells 
were suspended in 1% low-melting agarose and dissolved in deionized water. MR 
evaluation of the incubated cells was performed using a 3 T scanner (GE Medical 
System, Milwaukee, WI, USA). A human brain coil was employed to receive the MR 
signal. To emphasize the spatial resolution of the prepared solutions, 4 water-filled, 
plastic containers, each measuring 25x12x4 cm (length x width x depth), were placed 
along the 4 sides of the Petri dishes. A three-dimensional Multi Echo Recalled Gradient 
Echo T2* weighted sequence (MERGE) was acquired in the axial plane to visualize the 
content of the dishes. The technical parameters of the sequence were as follows: 
repetition time (TR) = 30 ms; Echo Time (TE) = 11.8 ms; EC=1/1 41.7 MHz; Field of 
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View (FOV) = 20 x 20 cm; Slice thickness = 1.2 mm/-0.09 over. The sequence was 
chosen because of its high sensitivity for paramagnetic agents and because of the good 
signal-to-noise (S/N) ratio.  
In-vivo experiments were performed with female Sprague-Dawley rats, aged 3 months, 
weighing 300-350 g. Rats were housed at a constant temperature of 24-25 °C and were 
subjected to a controlled 12 hour light-dark cycle; they had free access to water and 
diet. The experimental protocol followed the Principles of Laboratory Animal Care (EU 
Directive 2010/63/EU) and was approved by the Ethical Committee of the University of 
Pisa, Italy. MR evaluations of the rats were performed using a 3 T scanner (GE Medical 
System, Milwaukee, WI, USA). A human knee coil was applied to receive MR signal 
from the rats; all acquisitions were made at 19 °C. Each rat was studied separately 
twice: each time, the rats were positioned prone inside the reception coil, and the area 
of cell injection was clearly demarcated and included in the field of view (FOV). Animals 
were anesthetized using pentobarbital (50 mg/kg B.w., i.p.) (Sigma) at least 1 hour 
before starting the MR study. The MR evaluations were performed 1 day after the 
subcutaneous injection of 750-1000 human islets labeled with MWCNTs (islets 
incubated with 15 ug/ml of MWCNT for 5 days). Grafting was performed in either the 
absence or presence of a magnetic source. In the latter case, after the subcutaneous 
injection of the CNT labeled islets, a Neodymium magnet (N42, D30x15 mm) were 
placed in proximity to the injection site for 120 minutes to control the homing of the 
islets. A follow-up analysis was carried out 8 days after transplantation. A two-
dimensional, Fast Spoiled Gradient Echo (FSPGR) T1-WI imaging sequence with no fat 
suppression was acquired in the axial plane for each examination to visualize and 
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emphasize the contrast agent of the subcutaneous injection. The technical parameters 
of the sequence were as follows: repetition time (TR) = 275 ms; Echo Time (TE) = 3.2 
ms; EC=1/2 83.3 MHz; Field of View (FOV) = 10x9 cm; Slice thickness= 3.0 mm/0.3 
overlapping. The applied matrix was 320x224; the NEX was 2.0. Fat suppression was 
avoided to emphasize the signal-to-noise ratio of the thin, subcutaneous, dorsal region 
of the mice. The sequence was chosen because of its high sensitivity for super 
paramagnetic agents and because of the good signal-to-noise (S/N) ratio.  
 
Statistical analysis 
All results are expressed as mean ± SD. Statistical significance was evaluated using the 
two-tailed Student’s t-test or the analysis of variance (ANOVA) followed by post-test 
analysis, as appropriate. 
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RESULTS 
Multilayer nanoencapsulation 
As mentioned earlier, islet cell transplantation is a promising option for the treatment of 
type 1 diabetes and significant advances have been reported in the past years 16,46-48. 
However, a number of issues continue to limit the clinical success of islet 
transplantation in humans, including the chronic use of immunosuppression to prevent 
islet cell destruction of the recipient’s immune system 48-52. “Immune isolation” by the 
use of biocompatible materials with selective permeability is being accomplished to 
obtain macro- and  microencapsulation of the islets, able to protect the cells from 
immune attacks, while allowing the supply of nutrients to the beta cells and permit 
insulin release 53-57. More recently, nanomedicine tools have been applied in the field, 
and multi-layer-by-layer (MLBL) nanoencapsulation  methods have been  proposed. 
The concept of self-assembly of nanoparticles around cells was first introduced in the 
late 60's 58, and some years later the  concept was applied to form multi-layer nanofilms 
to be used in biological systems 59. Since then, layer-by-layer nanoencapsulation 
applications have become tools in various fields of biomedical applications 60-63, 
including islet studies 33,64-66. Several reports have shown the feasibility of the MLBL 
approach mainly with rodent, mice 33, 64-69 and pig 70 islets. Some information is 
available with human islets as well. Kozlovskaya et al 71 used hydrogen-bonded 
interactions of a natural polyphenol (tannic acid) with poly(N-vinylpyrrolidone) deposited 
on human islet surface via non-ionic layer-by-layer assembly, demonstrating beta cell 
viability and function for a few days in-vitro. In another report 24, different polycations 
 
 
28 
 
 
were attached in a self-assembly process to envelop human islets, with the use of poly-
allylamine, hydrochloride and poly-styrenesulfonate, sodium salt allowing maintainance 
of human islet function and beta cell ultrastructural features in-vitro. During this 
doctorate, the candidate has performed several studies  aimed at evaluating in-vitro and 
in-vivo (following xenotransplantation into diabetic mice) morphological, ultrastructural, 
functional, survival and molecular features of human islets treated by a multi-layer-by-
layer nanoencapsulation procedure. The procedures employed have been described 
above, and the results are reported below in detail. 
 
Multi-layer-by-layer nanoencapsulation was achieved by stepwise deposition of  
differently charged polymers (Chitosan/PSS) for up to 9 layers using electrostatic 
binding. The assessment of conformal coating was confirmed by depositing chitosan 
tagged with FITC in the seventh and ninth layer and assessed by using confocal/ 
fluorescence microscopy. As shown in figure 5a and b, the deposition of FITC-tagged 
chitosan in the external layers resulted in increased fluorescent intensity around the 
islets, thereby indicating the uniform distribution of the polyions around the extracellular 
architecture of the biological structure. More than 95% of the islets were 
nanoencapsulated by this method. Further to this, formalin fixed and paraffin embedded 
cross sections of the nanoencapsulated islets confirmed a uniform coating of islets 
assessed using fluorescence  microscopy (figure 5c). Additional studies with high-
resolution transmission electron microscopy (TEM) on nanoencapsulated islets (figure 
5d) further confirmed the uniformity of nanocoating and its intactness, with a measured 
thickness of 104 ± 4.2 nm Ultrastructural evaluation of nanocoated islets using electron 
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microscopy revealed the well maintained islet integrity, with well granulated beta and 
alpha cells and preserved ultrastructure indicating that the used polymers and the 
nanoencapsulation procedure were well tolerated by the islet cells in the short run.  
 
Figure 5: a, Fluorescence microscopy images of nanoencapsulated human islets visualized after 2-3 
hours from nanoencapsulion using chitosan tagged with FITC in the seventh and ninth layer; b, 3D 
images of confocal microscopy confirming the uniformity of nano coating; c, Cross-section of a 
nanocoated islet with incorporated layers of chitosan tagged with FITC (formalin-fixed and paraffin-
embedded), showing that the nano-layers appears to be completely cover the islet cell surface; d, TEM 
micrograph of the cross-section of an nanoencapsulated islet showing the uniformity of nanocoating, and 
insulin and glucagon granules. 
 
To study this issue in the long run, we cultured  nanoencapsulated and uncoated islets 
for 7 days; then, 15  randomly handpicked islets were stained with propidium iodide (PI) 
and hoechst 33342 (figure 6). Images of the stained islets were acquired using 
fluorescence microscopy and analyzed  using the image J software to count the number 
of live/dead cells. As also shown in figure  6e, cell viability of both uncoated (82 ± 10%) 
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and nanoencapsulated (84 ± 9%) islets was similar, confirming the safety of the 
procedure. 
 
Figure 6: Cell viability  assessed by staining the islet cells with propidium iodide (red) and hoechst 33342 
(blue) after 7 days of culture. The bright field microscopy images of both (a) uncoated and (b) 
nanoencapsulated islets are shown in the upper panels; the bottom panels show the fluorescence 
microscopy images of (c) uncoated islets and (d) nanoencapsulated islets (merged panels of propidium 
iodide (red) and  hoechst 33342 (blue). Blue indicates the live cells and red indicates the dead cells; (e) 
bar diagrams indicating the percentage of cell viability for both uncoated and nanoencapsulated human 
islets cultured for 7 days.  
 
Then, we investigated whether nanoencapsulation could protect human islets by the 
damage induced by inflammatory or metabolic toxic conditions. Uncoated and 
nanoencapsulated islets were incubated with a cocktail of cytokines (IL 1beta, 50 U/ml 
and IFN gamma,1000 U/ml) or 0.5 mM of palmitate for 72 hours. As shown in figure 7,  
the proportion of apoptotic beta cells, as assessed by electron microscopy, was 
significantly lower when the islets were nanoecapsulated, rather than uncoated.  
 
 
31 
 
 
 
Figure 7: a, Percentage of apoptotic cells present in the islets exposed to a cocktail of cytokines (IL-1 
beta, 50 U/ml and IFN gamma, 1000 U/ml) for 72 hours; b, percentage of apoptotic cells found in islets 
exposed to 0.5 mM of palmitate for 72 hours. Values are represented as mean±SD; *p<0.001 vs 
uncoated, control islets not exposed to either cytokines or palmitate and vs nanoencapsulated islets 
exposed to cytokines or palmitate. 
 
To determine whether these effects were indeed due to reduced entry of palmitate by 
encapsulation, we studied the uncoated and nanoencapsulated human islets after 
incubation with palmitate by metabolic labeling (click-chemistry). Both uncoated and 
nanoencapsulated islets were metabolically labeled with azide-containing palmitic acid 
for 8-12 hours, following which the detection was assessed by counter labeling with 
alkyne-tagged fluorescent molecule Alexa Fluor®-594 (click-reaction between azido and 
alkyne molecule). The presence of palmitic acid was finally visualized using 
fluorescence microscopy (figure 8), showing reduced fluorescence in the coated islets, 
including when cross sections were studied. These results were further confirmed by 
the measures of relative fluorescence units (RFU), assessed using a fluorescence 
spectrophotometer, which demonstrated that uncoated islets had significantly (p<0.003) 
higher fluorescence intensity when compared to nanoencapsulated islets. 
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Figure 8: Analysis of palmitic acid entry into cells by fluorescence microscopy. Uncoated and 
nanoencapsulated human islets were metabolically labeled with 100 µM of palmitic acid-azido for 8-12 
hours and allowed to react with click-iT cell reaction buffer (440 µl of 1X click-iT reaction buffer; 10 µl of 
100 mM CuSO4; 50 µl of click-iT cell buffer additive; 50 µl of 1mg/ml Alexa fluor 594-alkyne); upper panels 
(a1) cross sections of metabolically labeled uncoated islets stained with DAPI, (a2) presence of palmitic 
acid-azide counter stained with Alexa flour 594, (a3) merged panels showing the presence of 
fluorescence palmitic acid inside the uncoated islets; bottom panels (b1) cross sections of 
nanoencapsulated islets stained with DAPI, (b2) showing thepresence of very few fluorescence 
molecules, (b3) merged panels confirming the presence of very few  fluorescence molecules inside the 
nanoencapsulated islets.(arrows (→) indicate the presence of palmitic acid);  Figure 8C: bar diagram 
showing relative fluorescence units of uncoated vs nanoencapsulated islets (p<0.003) observed using 
fluorescence spectrophotometry . 
 
Extensive studies were then performed to evaluate the insulin secretion functional 
properties of the nanocoated islets. We cultured both the uncoated and 
nanoencapsulated islets for 7 days and compared their function by glucose stimulated 
insulin secretion (GSIS). The glucose concentration of 3.3 mM glucose was used to 
assess basal insulin secretion and the glucose concentration of 16.7 mM was used to 
determine stimulated insulin secretion. Both batch incubation and perifusione studies 
were performed. As shown in figure 9,uncoated and nanoencapsulated islets exhibited 
similar insulin secretion levels (nanoencapsulated islets: 40 ± 33 μU/ml at 3.3 mM 
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glucose and 143 ± 111 μU/ml at 16.7 mM glucose; uncoated islets: 32 ± 22 μU/ml at 3.3 
mM glucose and 135 ± 96 μU/ml at16.7 mM glucose). Accordingly, there was no 
significant difference in the glucose stimulation index values (4 ± 2.4 with coated islets 
vs 4.4 ± 2.3 with nanoencapsulated islets).  
 
Figure 9: Static insulin secretion in response to glucose 3.3 mM and 16.7 mM from uncoated and 
nanoencapsulated islets (left panel); Glucose stimulation index of  uncoated and nanoencapsulated islets 
derived from the ratio of insulin secretion at 16.7mm  divided by 3.3 mm glucose. 
 
Dynamic insulin secretion of the nanoencapsulated islets was studied and compared 
with that of the uncoated islets by using a perifusion system. As shown in figure 10, 
nanoencapsulated and uncoated islets had a similarly regulated pattern of glucose 
stimulated insulin secretion, with the acute phase starting rapidly after the increase of 
glucose concentration and a return towards basal values afterwards.   
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Figure 10: Dynamic insulin secretion from uncoated and nanoencapsulated human islets in response to 
different concentrations of glucose over the time. Fold changes in insulin release in response to the 
glucose challenges as a function of time was studied using a temperature controlled perifusion system. 
The values are represented as mean±SD. 
 
Of interest, in an additional set of experiments, we observed that this 
nanoencapsulation approach was able to protect, at least in part, the beta cell function 
from cytokine and palmitae induced cytostatic actions. In fact, insulin secretion, 
expressed as glucose stimulation index (GSI) (insulin secretion at 16.7 mM glucose 
divided by insulin secretion at 3.3 mM glucose) was reduced when uncoated islets were 
incubated with a cocktail of cytokines (IL -1beta -50 U/ml and IFN gamma 1000 U/ml) or 
0.5 mM palmitate (figure 11): however, a better insulin secretion was found when the 
islets had been nanoencapsulated, showing that the coating was able to exert some 
degree of protection. 
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Figure 11: Glucose stimulation index of islets exposed to a cocktail of cytokines (left panel ) or lipotoxic 
conditions (right panel), showing that the nanoencapsulated islets are protected from cytokine and 
palmitate functional damage.   
 
To assess whether nanoencapsulation offers effective protection against host immune  
rejection, we performed a xenogeneic islet transplantation by transplanting 
approximately 400 human islets/graft under the kidney capsule of C57BL/6 mice with 
diabetes induced by streptozotocin. As shown in figure 12, we observed a significant 
decrease in the random blood glucose values in mice transplanted with 
nanoencapsulated islets in the first week of post-transplantation, which was maintained 
throughout the study period. On the other hand, mice transplanted with uncoated islets 
showed progressive increase of blood glucose levels. We also investigated the in vivo 
function of the transplanted islet graft after 15 days of post-transplantation by acutely 
challenging the mice by with an intraperitoneal glucose tolerance test (IPGT). Results 
showed that mice transplanted with nanoencapsulated islets had a normal response to 
acute glucose challenge (figure 12).  
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Figure 12: In vivo assessment of transplanted islet grafts. Random blood glucose of mice transplanted 
with uncoated or nanocoated human islet graft is shown in the left panel, indicating normal or near normal 
glycemic values with nanoencapsulated islets. Intraperitonial glucose tolerance test performed after 15 
days post-transplantation showed the appropriateness of glycemic control by nanoencapsulated islet 
(right panel).    
 
One month after transplantation, kidneys bearing the islet grafts were recovered (figure 
13) and histological analysis performed. 
 
Figure 13: Images showing the presence of islet graft in the kidney capsule after one month post-
transplantation.  
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Hematoxylin/eosin staining (figure 14) revealed better preserved islet cell architecture 
with the nanoencapsulated tissue, which was confirmed by Chromogranin A staining 
(that identifies endocrine cells).  
 
Figure 14: Histological analysis of explanted graft sections for hematoxylin/eosin and Chromogranin A 
staining reveals that nanoencapsulated islets have a better structure 
 
Immunofluorescence staining of insulin  and glucagon was performed on the explanted 
islet graft sections in order to assess the ability of beta and alpha cells to synthesize 
and store insulin and glucagon (figure 15). Clusters of well preserved islets with strong 
insulin and glucagon immunostaining were found in the grafts with nanoencapsulated 
islets; however, such stainings were very weak when uncoated islets had been 
transplanted.   
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Figure 15: Representative confocal microscopy images showing Immuno fluorescence staining of 
explanted islet grafts after 1 month post-transplantation with insulin (red) and glucagon (green) staining 
showing well preserved beta and alpha cells in mice transplanted with nanoencapsulated islets.  
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To determine the ability of nanoencapsulation in protecting the islets from infiltrating 
host immune cells, immunohistochemistry staining for MOP (myeloperoxidase), CD45 
(T-lymphocyte) and CD68 (macrophages) was carried out on consecutive, paraffin-
embedded sections of explanted islet grafts. As shown in figure 16, grafts with 
uncoated islets were found to have many more positive cells for all the immune cell 
biomarkers, whereas the grafts with nanoencapsulated islets were found to have much 
less infiltrating cells. 
 
 
Figure 16: Immunohistochemical analysis of cross sections of islet grafts containing uncoated or 
nanoencapsulated human islets. Kidney sections were stained for the presence of immune cells (MOP+, 
CD45+ and CD68+ cells).  
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Additional morphological analyses were performed. Figure 17 represents the semithin 
resin staining of explanted islet grafts after one month post-transplantation. This method 
further confirmed the presence of a number of well preserved islets with normal cell 
morphology in the case of nanoencapsulated islets, with  also signs of revascularization. 
Moreover, we also observed the presence of collagen fibers and mast cells around, but 
not within the islets. 
 
Figure 17: a, Semithin resin staining of islet grafts showing the presence of numerous nanoencapsulated 
islets (→); b, Cross sections of graft showing the normal morphology of an islet with capillaries around; c, 
Higher magnification of graft showing signs of vascularization in the transplanted islets and also the 
presence of collagen fibers around, but not within the islets.   
 
Finally, the explanted grafts were studied in term of ultrastructural features using 
electron microscopy. Representative images of electron micrograph are shown in figure 
18, indicating well maintained islet cells with insulin, glucagon or somatostatin granules;  
no signs of apoptosis or necrosis in the explanted graft of nanoencapsulated islets were 
observed. The presence of nanocapsules around the islets was also seen, 
demonstrating the stability of the system.  
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Figure 18.: TEM images of transplanted grafts with nanoencapsulated islets. a, The presence of normal 
islet cells (β,α & δ) is shown,  with no ultrastructural changes. b, micrographs showing the presence of 
insulin and glucagon granules close to islet cell plasma membrane; c, Intact nanocapsule after one month 
from transplantation.  
 
A significant issue limiting the efficacy of transplantation of encapsulated islets has been 
the comparatively large size of the capsules even generated by microencapsulation. In 
traditional microencapsulation approaches, in fact, islets are incorporated within 
capsules of uniform size, determined by the geometry of a jet-making apparatus. As 
such, the capsule size is adapted for the largest of islets, resulting in thick capsules on 
the bulk of the islets. This may limit islet cell oxygenation and impair the regulation of 
insulin secretion and, in addition, the thick capsules increase the volume of the total 
transplant, thus limiting selection of transplant sites 74-76.  
In this part of the doctoral project an extensive evaluation of the feasibility of human islet 
nanoencapsulation by a layer-by-layer procedure has been successfully performed. As 
mentioned earlier, this approach has been conceived some years ago, and is being 
developed also in terms of possible automated systems 77-80. The procedure involves 
the alternate deposition of polymer electrolytes of positive or negative charge around 
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the islets. The amount of electrolyte deposited in each layer is self-limited, and 
independent of time and concentration. This conformal protection may conceivably 
guarantees further improvement as for the kinetics of insulin release, due to absence of 
dead space around the islets. However, although it has been reported that, mainly 
depending on electrolyte selection, insulin secretion function from  nanocoated islets 
can be well maintained, studies in this regard are still scanty. In vitro glucose-stimulated 
insulin release from rat islets protected with alternate layers of phosphorylcholine-
derived polysaccharides (chitosan or chondroitin-4-sulphate) and alginate has been 
reported to be similar to that of uncoated islets33. Depending also on the number of 
layers, nanocoating of human islets with [poly-(allylamine hydrochloride)] (PAH) and 
[poly-(styrenesulfonate)] (PSS) was associated with preserved secretion of insulin in 
response to 3.3 and 16.7 mmol/l glucose 24; however, the use of [poly-
(diallydimethylammonium chloride)] was accompanied by blunted insulin release 24. In 
another study, PAH and PSS were found to damage human islet cells 64, whereas the 
formation of PEG-rich coating via layer-by-layer self-assembly of poly(l-lysine)- g-
poly(ethylene glycol)(biotin) and streptavidin allowed better insulin secretion function 64. 
Our results indicate that human islets nanoencapsulated with chitosan and PSS 
maintain in-vitro morphological integrity and functional competence, and can restore 
long-term normoglycemia in diabetic mice. Potentially, this system could be scaled up to 
be applied in the human setting.  
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Anti-inflammatory nanostructures 
Given the role of innate immunity and inflammation in affecting islet transplantation, we 
explored the potential use of zinc oxide nanoparticles (ZnO NPs) to protect islet cells in 
this regard. ZnO NPs are  widely used in the field of biomedicine, pharmacology, food 
processing and engineering industries. They were found to have a potential effect on 
both gram-positive and gram-negative bacteria such as Staphylococcus aureus and 
Streptococcus mutans, Lactobacillus, E. coli 81,82. Recent reports further confirmed that 
they can be used as a prophylactic agent against bacterial infections 83,84. The effects of 
nanoparticles mainly depend on their shape, size and purity. Studies by Jones et al. 
have shown that ZnO NPs with a size of 8 nm have a more toxic effect than the larger 
sized (50-70 nm) ZnO NPs 85-87. Another study has reported that there was an inverse 
relationship between the size of nanoparticles and cytotoxicity in mammalian cells 87,88. 
Several additional studies have confirmed  the toxic effects of ZnO NPs 89-91, with one 
study by Taccola L et al., indicating the toxicity may depend on various factors like 
physical and chemical characteristics (size, shape and purity) and functionalization 
methods used for the dispersion of the nanoparticles, which can have different effects in 
biomedical applications 92. Different groups have reported that the toxic effect ZnO NPs 
varies with different cell lines, for example ZnO NPs have shown to have an adverse 
effect on neuroblastoma cells 93, human liver cells 94, lung bronchial epithelial cells 95, 
vascular epithelial cells 96 and retinal ganglion cells 97 but whereas with reference to  
human primary T-cells they have a negligible toxicity effect 98. Part of the doctorate work 
aimed to evaluate if the use of ZnO NPs could potentially protect beta cells when these 
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face inflammatory cell attack. In such a case, we first assessed if the nanoparticles 
could impact on beta cell function and survival. 
To investigate the effect of ZnO NPs on INS-1E beta cells, we incubated the beta cells 
with varying concentration of ZnO NPs (10, 25 and 50 μg/ml) for two different time 
periods (24 and 72 hours). As shown in figure 19, we observed that increase in 
concentrations of ZnO NPs greater than 10 μg/ml reduced the viability of INS-1E beta 
cells. The appropriateness of 10 μg/ml concentrations was confirmed by assessing cell 
viability using Hoechst 33342 and propidium iodide staining (figure 20). This showed 
that INS-1E beta cells incubated with 10 μg/ml of ZnO nanoparticles had >90% viability 
for up to 1 week in culture. 
 
 
Figure 19: Percentage of cell viability measured using MTT assay with different concentration of zinc 
oxide  nano particle after 24 and 72 hours of incubation.  
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Figure 20: Cell viability  assessed by staining INS-1E beta cells with propidium iodide (red) and Hoechst 
33342 (blue) after 7 days of culture (left panel);  the proportion of living cells is reported in the right panel.   
. 
Intracellular ZnO measurement of INS-1E beta cells incubated with different doses of 
ZnO nanoparticles for up to 24 hrs is shown in figure 21, with the results indicating that 
there was a dose-dependent increase in the intracellular zinc concentration with 
increase in ZnO NPs concentrations.   
 
Figure 21: Dose dependent uptake of zinc oxide nanoparticles in INS-1E beta  cells after 24 hours of 
incubation 
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Electron micrograph images of human islets incubated with 10 µg/ml of zinc oxide 
nanoparticles for 7 days are shown in figure 22. The results indicated that ZnO NPs 
enter human islet cells, with the presence of ZnO NPs inside and near the plasma 
membrane of pancreatic beta cells. Interestingly, human beta cells showed no sign of 
apoptosis and well maintained  ultrastructure after 7 days of incubation with 10 µg/ml 
ZnO NPs, confirming that this concentration is compatible with normal human beta cell 
survival.   
 
Figure 22: TEM micrograph cross section of human islets incubated with 10 µg/ml of zinc oxide for 7 
days;  a and b show the presence of  zinc oxide in vacuoles, whereas c and d shows the presence of zinc 
oxide inside and near the plasma of beta cells in the islet. 
 
Glucose stimulation index (insulin release at high glucose over insulin release at low 
glucose), a measure of beta cell function, is shown in figure 23 for INS-1E cells and 
human islets. Insulin secretion from both INS-1E beta cells and human islets was not 
affected by exposure to 10 µg/ml of ZnO NPs for up to 7 days. 
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Figure 23: a, Glucose stimulation index of INS-1E cells treated with zinc oxide  for  7 days; b, Glucose 
stimulation index of human islets  treated with zinc oxide  for 7 days. 
 
To determine if there could be an anti-inflammatory effect of ZnO NPs, we  cultured  
PBMCs with different concentrations of zinc oxide nanoparticles for 12, 24 and 48 hrs. 
As reported in figure 24 (left panel), increased concentrations of ZnO NPs decreased 
the viability of PBMCs at all the given time points, but not significantly so. Measurement 
of monocyte chemotactic protein 1 (MCP-1) release in the PBMCs culture medium 
showed a similar trend  (figure 24, right panel). 
 
Figure 24: Cell viability   of PBMCs cells treated with different doses of zinc oxide nano particles with 
different time points (left);  MCP-1 release from  PBMCs cells treated with different doses of zinc oxide 
nano particles  for 24 hrs (right). 
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Similar results were obtained when the insulin release was measured from human islets 
co-cultured with PBMCs along with different doses of ZnO nanoparticles (figure 25). 
 
Figure 25: Glucose stimulation index from human islets co-cultured with PBMCs along with different 
doses of ZnO nano particles. 
 
Therefore, in the present part of the project we have investigated the effects of ZnO 
nanoparticles on INS-1E beta cells and human islets. The potential utility of ZnO NPs in 
the treatment of autoimmunity disease has been recently suggested in a study25, where 
the data of the authors demonstrated that ZnO NPs could induce toxicity in a cell-
specific and proliferation-dependent manner. Mechanisms of toxicity appeared to 
involve the generation of reactive oxygen species (ROS), with proliferating cells 
producing higher inducible levels. This has been confirmed in other studies 92. There is 
also evidence that treatment of diabetic patients with Zn leads to a more balanced 
oxidant/antioxidant equilibrium99. Finally, it has been found that zinc can have a 
protective effect on diabetic nephropathy 100,101. However, to date, there were no studies 
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to show the effects of ZnO NPs on pancreatic beta cells. We have demonstrated that 
ZnO NPs at a concentration of 10 µg/ml is compatible with normal human beta cell 
survival and function for up to 7 days of incubation. However, at this concentration the 
nanomaterial was not able to modify the properties of PBMCs for up two days of culture 
(longer periods of incubations are not compatible with PBMCs survival). Therefore, this 
section of the doctoral project was only partially successful. 
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Nanoparticle-guided homing 
Type 1 diabetes is one of the most common endocrine and metabolic chronic disorders, 
characterized by the destruction of insulin-producing beta cells102. Islet cell 
transplantation is considered a promising therapy to restore normoglycemia through 
beta cell replenishment, with improving results over the past few years103-105. However, 
long-lasting insulin independence after islet grafts remains elusive, and non-invasive 
methods to monitor the islets after transplantation is highly advisable. Although a few 
studies have been performed with rodent and porcine isolated islets106-108, relatively little 
information is available for the use of human islets.  
Two groups have labeled isolated human islets and transplanted them into type 1 
diabetic patients. In 2008, Toso and coll. treated isolated human islets with 
ferucarbotran (Resovist®), followed by transplantation into type 1 diabetic subjects109. 
Patients became insulin-independent after transplantation, and the islets were identified 
as hypodense spots within the liver109. Malosio and coll. developed a procedure to label 
human islets with the clinically approved agent Endorem®, showing well maintained in-
vitro function and viability, and islets were localized in the livers of transplanted mice by 
MRI110 afterwards; the method was preliminarily applied in the human setting111. 
Additional studies have been performed with human islets in-vitro and by transplantation 
into experimental animal models. In these studies, Resovist®112, Endorem®112,113, 
rhodamine-perfluorooctylbromide or rhodamine-perfluoropolyether109 nanoparticles 
have been employed. However, several of the clinically available iron containing 
contrast agents have a relatively high overall incidence of side effects (approximately 
10%)114, and in some cases, they have been removed from the market115. In addition, 
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misinterpretation of the obtained experimental data may occur because macrophages 
can phagocytose labeled cells and actively move them from the site of cell 
implantation116.  
In an effort to add information in this area, we tested multiwall carbon nanotubes as 
labeling compounds for use with isolated human islets. Carbon nanotubes are 
molecules made of folded graphite sheets, having unique physical, chemical and 
functional properties and representing a potential tool for several clinical and research 
applications117-122. According to their shape and structure, they can be identified as 
single-walled (SWCNTs) or multiwall (MWCNTs) carbon nanotubes117. SWCNTs are 
rolled into single cylindrical structures, whereas MWCNTs are concentric layers of 
graphite sheets rolled into cylindrical structures120. Compared with the other available 
contrast agents, MWCNTs seem to have a number of potential advantages, including 
longer magnetization of labeled cells, the possibility of use with mesenchymal stem cells 
and their possible application in drug delivery systems117-121. Due to the extensive use 
of these nanomolecules as MRI contrast agents122-125, we assessed the potential of 
MWCNTs to label insulin-producing beta cells and evaluated their biological effects and 
contrastographic properties.  
Qualitative analysis of cellular internalization of Endorem® and MWCNTs in INS-1E was 
assessed using Prussian blue staining and visualized using bright field microscopy. The 
method confirmed the presence of iron particles in the cytoplasm of INS-1E beta cells 
after exposure to either (50 µg/ml) Endorem® or MWCNTs (15 µg/ml) (figure 26).  
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Figure  26: Prussian blue staining of INS-1E cells labeled with Endorem® or MWCNTs after 7 days of 
culture. Arrows indicate the contrast - agent-containing cells.  
 
Electron microscopy was used to evaluate human islets after labeling with the two 
contrast agents. MWCNT particles were found very close to the cell membrane and also 
in the act of passing through it (figure 27), indicating the capability of MWCNTs to 
directly penetrate the plasma membrane of beta cells. Furthermore, we also observed 
endocytosis as an internalization mechanism.  
 
Figure  27: Electron microscopy images of labeled human islet beta cells showing 1 and 2, MWCNTS 
entering the cell; 3, MWCNTs in the cytoplasm after penetration; 4 and 5 MWCNTs in the process of 
undergoing endocytosis; 6, MWCNTs within the endocytosis vesicles in the cytoplasm Magnification: 
x160000 in panels 1-5, and x 96000 in panel 6. 
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In fact, MWCNTs were found in the cell membrane, which engulfed the vesicles and 
internalized the particles into the cytoplasm. These observations indicate that the entry 
mechanism of MWCNTs into beta cells occurred through direct membrane translocation 
or endocytosis.  
 
Figure  28: 1) Electron microscopy images of labeled human islet beta cells showing endocytosis of 
Endorem (→) in beta cells. 2) Endorem in vacuoles. 3) Endorem in a lysosomal body. Magnification:        
x 64000. 
 
Additionally, we observed a strong interaction of Endorem® with beta cell membranes 
(figure 28), which allowed the intracellular translocation of the particles into vacuoles, 
followed by fusion into large lysosomes. With either agent, no particles were detected in 
the nuclei, and the cytoplasmic organelles showed normal ultrastructure. Of potential 
interest was the observation that MWCNTs and Endorem® did not enter alpha cells 
(figure 29), suggesting different capabilities of the various human islet cells to interact 
with the compounds. 
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Figure  29: Electron microscopy images of human islet alpha cells (recognizable from the presence of 
glucagon granules, GG) showing no internalization of MWCNTs or Endorem® after 7 days of incubation. 
1: MWCNTs (arrow) close to an alpha cell; 2; MWCNTs adjacent to the plasma membrane; 3: Endorem® 
particles (squared) in contact with the plasma membrane, but not in the cytosol, of an alpha cell; 4: 
lysosomes showing no Endorem® particles inside). 
 
 Basal and stimulated insulin release (reported also as stimulation index, i.e., insulin 
release at high glucose over insulin release at low glucose) from INS-1E cells, either 
pre-exposed or not to 50 µg/ml Endorem® or 15 µg/ml MWCNTs is reported table 1. 
Following the culture performed with additional concentrations of Endorem® (10, 100 
and 200 µg/ml) or MWCNTs (5, 50 and 100 µg/ml), no significant changes in insulin 
secretion were observed, with stimulation index values ranging from 97.1±26.7% to 
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132±44.5% of the control cells with Endorem® and from 85±27% to 131±62% with 
MWCNTs.  
Condition 3.3 mM glucose 16.7 mM glucose Stimulation index 
INS-1E beta cells 
Controls 15.4±4.2 58.2±18.6* 3.8±1.0 
Endorem® 16.6±7.8 30.4.2±12.1* 2.0±0.5 
MWCNTs 13.2±3.7 48.1±26.3* 3.3±1.9 
Human islets 
Controls 38.9± 25.3 162.9±106.5* 6.1±5.4 
Endorem® 24.7± 8.4 148.1±144.6* 5.59±4.6 
MWCNTs 32.0± 9.7 162.1±123.2* 5.0±4.3 
 
Table 2: Insulin secretion (μU/ml and stimulation index) in response to acute glucose stimulation of INS-
1E cells and human islets labeled with Endorem® (50 μg/ml) or MWCNTs (15 μg/ml), after 7 days of 
culture (results are from at least 5 separate preparations, each studied in triplicate). *p<0.01 vs 3.3 mM 
glucose 
 
 
The secretion of insulin from human islets in response to glucose stimulation is also 
reported in table 1, showing good and similarly maintained glucose responsiveness 
under every 7-day incubation condition (control medium, Endorem® or MWCNTs). 
 
To study the potential biological toxicity related to the compounds, INS-1E beta cells 
were incubated for 7 days with the different concentrations of Endorem® or MWCNTs 
used in the insulin secretion studies. By using PI and Hoechst 3342 staining (figure 30), 
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it was found that the viability was similar at any experimental condition and ranged from 
96 to 99%.  
 
Figure  30: Representative fluorescence microscopy images of INS-1E cells after staining with nuclear 
dyes (Hoechst 33258, blue; propidium iodide, red) after 7 days of culture with control medium (a), 
Endorem® (b) or MWCNTs (c). 
 
The proportion of beta cells in human islets that were cultured for 7 days with either 
control medium, a medium with 50 µg/ml Endorem® or 15 µg/ml MWCNTs were 69±1% 
(214 islet cells counted), 67±1.5% (263 islet cells counted) and 63±4% (286 cells 
counted), respectively, as assessed using electron microscopy. Accordingly, no 
difference in the amount of apoptotic or necrotic beta cells (which were approximately 
2%) was found between the different conditions. 
 
To assess whether cells labeled with the compounds under investigation could be 
visualized using MRI, INS1-E cells and human islets were labeled with 50 µg/ml 
Endorem® or 15 µg/ml MWCNTs, and studied after 3, 7 and 15 days, following 
suspension in 1% agarose gel. The MRI was performed using a 3T MR Scanner. As 
shown in figure 31, both labeled INS-1E cells and human islets were visualized on T2* 
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weighted images as hypointense areas that were detectable up to 15 days from 
labeling.  
 
Figure  31: Magnetic resonance imaging (MRI) of INS-1E cells and human islets labeled with Endorem® 
or MWCNTs and studied at different times after labeling (arrows indicate the imaged cells/islets). Cells 
were embedded in 1% agarose gel and visualized through clinical grade 3 T MRI scanner with a 
repetition time of 30 ms, echo time of 11.8 ms, with field of view of 20x20 cm and slice thickness of 1.2 
mm/-0.9 over.  
 
Human islets labeled with MWCNTs and transplanted under the subcutaneous tissue of 
the non-diabetic Sprague-Dawley rats were tracked using 3 T MR scanner after 1 day 
and 8 days of transplantation. Representative T2-weighed images with hypointense 
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areas are given in figure 32. On day 1 post-grafting, islets transplanted in the presence 
of a magnet had better and denser signal than the islets transplanted without a magnet, 
which showed a more disperse appearance. On day 8, the signal was still partially 
detectable in islets grafted with the magnet, but barely so in the case of transplants 
without the use of a magnet.  
 
Figure  32: In-vivo magnetic resonance imaging (MRI) of MWCNTs labeled islets transplanted under the 
subcutaneous tissue of rats after 1 and 8 days from transplantation. a and b: MRI of MWCNTs labeled 
islets transplanted without a magnetic field; c and d: MRI of MWCNTs labeled islets transplanted with a 
magnetic field. 
 
Finally, we performed some experiments to evaluate if MWCNTs could be included in 
the chitosan and PSS layers. As shown in figure 33, electron microscopy did indeed 
show the presence  of this tracking agent within the nanocapsule. 
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Figure  33: MWCNTs functionalized with Chitosan and PSS; human islet nanoencapsulated with 
Chitosan-MWCNTs and PSS-MWCNTs contain MWCNTs in the nanocapsule. 
 
More interestingly, magnetic resonance imaging of human islets nanoencapsulated 
together with MWCNTs was able to identify the tracked islets (figure 34). 
 
Figure  34: Magnetic resonance imaging (MRI) of human islets nanoencapsulated with MWCNTs and 
functionalized Chitosan and PSS (arrows indicate the imaged islets). Human islets were embedded in 1% 
agarose gel and visualized through clinical grade 3 T MRI scanner with a repetition time of 30 ms, echo 
time of 11.8 ms, with field of view of 20x20 cm and slice thickness of 3.0 mm/-1.9 over. 
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Therefore, in this part of the doctorate project, a comparative study of the biological 
effects induced by MWCNTs and Endorem® was performed. After 7-days of continuous 
incubation of the particles with INS-1E, the cell survival was found to be similar to the 
control at any concentration tested (evaluated using the PI dye exclusion assay). 
Potential cell toxicity was also evaluated in human islets. The proportion of beta cells in 
human islets for both Endorem® and MWCNTs was found to be similar to the control, 
and no difference was found in the amount of apoptotic or necrotic beta cells, which was 
approximately 2% and assessed using electron microscopy. No particles could be 
detected in nuclei and no damage to the cytoplasmic organelles was found. Basal and 
stimulated insulin release were assessed in both INS-1E cells and human islets, and no 
significant change in insulin secretion was observed among the groups (Endorem®, 
MWCNTs, control).  
Incubation of INS-1E cells with Endorem® or MWCNTs causes progressive intracellular 
particle accumulation, as suggested by the histological analysis using Prussian blue 
staining. To study the entry mechanisms, electron microscopy analysis was performed 
directly on human islets. TEM is routinely used to clarify the cell internalization pathway 
of particles. Over the last ten years, several groups have shown that MWCNTs can be 
used as efficient carriers for the delivery of therapeutic and diagnostic small and large 
molecules inside cells126,127. However, diverging data have been reported concerning 
the exact mechanism of cellular internalization. Several mechanisms have been 
proposed, including nanotube uptake through an energy-independent, non-endocytotic 
pathway that involves insertion and diffusion of nanotubes across cell membranes128, 
active ingestion of the nanotubes by macrophages129, and clathrin-dependent receptor 
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mediated endocytosis130. The discrepancy in uptake mechanisms has been partially 
clarified through careful scrutiny of the physico-chemical properties of MWCNTs. 
Generally speaking, strong energy-dependent cellular internalization 
(endocytosis/phagocytosis) is involved in long nanotubes35, aggregated MWCNTs131, 
132, complex (covalent or otherwise) proteins136, oligonucleotides137, specific cell ligands 
(including growth factors138) and monoclonal antibodies138. Diffusion mechanisms have 
been reported for single short nanotubes35 or nanotubes functionalized to prevent the 
formation of supra-molecular complexes136. They can act as tiny, straight ‘‘nano-
needles’’ that are able to penetrate the cell membrane more efficiently than longer 
nanotubes (i.e., >1 µm length) or macromolecule/MWCNT complexes, which are often 
arranged in a ‘‘ball’’ or bundled shape. For the first time, we now show that MWCNTs 
enter human beta cells through direct membrane penetration (short tubes) or an 
endosomic pathway (bundled shape nanotubes or cluster). 
A similar investigation was performed on human islets treated with Endorem®. It is 
known that the biocompatible coating (dextran) of Endorem® plays a role in 
nanoparticle uptake by macrophages. Systemically applied SPIONs are quickly taken 
up by phagocytic cells, mainly macrophages, and the cellular uptake involves scavenger 
receptor SR-A-mediated endocytosis137. SPIONs degrade in some intracellular 
endosomes/lysosomes between days 3 and 5 after administration. Specifically, SPION-
containing endosomes were found to fuse with lysosomes, causing rapid dissociation of 
the iron core to soluble Fe(III) at low pH, and progressively incorporated into the iron-
storing proteins138. We found Endorem® translocation into beta cell vacuoles, followed 
by fusion into large lysosomes. Neither MWCNTs nor Endorem® entered the alpha 
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cells. Although the mechanisms responsible have not been investigated, it is known that 
pancreatic beta and alpha cells have very different behaviors regarding several 
functions, including plasma membrane properties, such as electrical excitability and 
exocytotic phenomena139, 140. Although more work is clearly needed in this regard 
(including longer incubation times), this finding could be exploited for cell-specific 
labeling of human islets. 
Collectively, these results confirm the negligible cytotoxic profiles of both Endorem® 
and MWCNTs. Once this point was verified, and considering that particles are 
preferentially internalized in beta cells over alpha cells, we tested the ability of MWCNTs 
to label human islet and beta cell for MRI monitoring. MRI is an extremely versatile 
imaging technique and particularly suitable for testing novel medical therapies, as it is 
available in pre-clinical and clinical platforms, allowing a seamless transition from the 
laboratory into the clinic.  
The present study shows for the first time that MWCNTs are powerful in-vitro and in-
vivo contrast agents for the labeling of beta cells, including those of human origin. 
MWCNTs at 15 ug/ml show similar effects to Endorem® 50 ug/ml in MRI labeling of 
both INS-1E cells and human islets for up to 7 days of incubation. This result is relevant 
because the amount of Fe per mass in MWCNTs is approximately 2.5%, while in 
Endorem®, it is approximately 76%. The reduced signal at day 8 compared with day 1 
after transplantation can be reasonably attributed to rapid islet cell destruction by the 
recipient immune system, as previously reported in a xenogeneic (human-to-rat) islet 
transplantation model141. This study also shows, in a preliminary way, the possibility of 
guiding islet engraftment. Our previous studies demonstrated that, when cells are 
 
 
63 
 
 
cultured in a medium containing MWCNTs, they interact with the particles, internalize 
them and become “magnetized”; thus, they are able to respond to an external magnetic 
field26, 36,142. Additionally, we demonstrated in a rat model that MWCNT labeled cells can 
be transplanted and easily controlled and localized in the target site using low intensity 
magnetic fields121. In the present paper, we show, for the first time, that this approach 
can be used to allow site-specific, guided localization of human islet grafts containing 
MWCNTs, which is of potential interest in pre-clinical and clinical islet transplantation, in 
particular when the implantation is performed at specific sites, such as subcutaneous or 
intramuscular spaces143.  
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CONCLUSIONS 
The doctorate project described in this thesis was designed to explore the use of 
nanomedicine in the field of type 1 diabetes, a devastating metabolic disease, with the 
aim of making steps ahead in the perspective of isolated islet transplantation. As such, 
the main objectives of the research were: to develop a system to immunoprotect 
isolated human islets by novel multilayer nanosystems, with maintainance of in vitro 
viability and function of beta cells; to cure chemically induced diabetes in laboratory 
animals by transplantation of nanocoated human islets; to test the feasibility of 
transplanting human islets into laboratory animals using nanoparticle-guided tracking 
and homing. 
During the research period we were indeed able to develop and implement a multi-
layer-by-layer (7 to 9 layers) islet nanocoating system, by electrostatic binding of 
differently charged polymers (chitosan and PSS). Nanocoated human islets maintained 
long-term in vitro morphological and ultrastructural integrity, with beta cell survival 
similar to that of non-encapsulated islets. Insulin secretion in response to glucose was 
well preserved both quantitatively as well as in terms of dynamic hormone release, as 
assessed by perifusion studies. More interestingly, when nanoencapsulated human 
islets were transplanted under the kidney capsule of non-immunosuppressed diabetic 
mice, normal/near normal blood glucose levels were restored for the whole study period 
(one month). Histology of the explanted grafts showed minimal immune cells infiltration 
of the coated islets, with well represented insulin and glucagon containing cells and 
normal beta cell ultrastructural appearance. Notably, signs of graft revascularization 
were also shown.  In addition, we tested the possibility of using zinc oxide nanoparticles 
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as a mean to chemically protect the islets in the perspective of better facing the 
inflammatory milieu in the implantation site in-vivo. Previous work has in fact 
demonstrated that zinc oxide may interfere with the function and survival of rapidly 
proliferating cells, such as those of the immune system. We were able to demonstrate 
that 10 μg/ml of these nanoparticles are perfectly compatible with normal human beta 
cell homeostasis, as demonstrated by morphological, insulin secretion and turn over 
studies. If this concentration of zinc oxide nanoparticles (shown by our experiments to 
enter the beta cells) can modulate the action of immune cells remains to be  
determined. 
Finally, for the first time we have demonstrated that MWCNTs are powerful in vitro and 
in vivo contrast agents for the labeling of beta cells, including those of human origin. 
MWCNTs at 15 ug/ml was effective in this regard, at the same time showing no 
apparent impact on beta cell properties. In addition, our study also demonstrates, in a 
preliminary way, the possibility of guiding islet engraftment. Beta cells cultured in 
medium containing MWCNTs  internalize the particles and become “magnetized”, 
becoming able to respond to an external magnetic field. As a matter of fact, we showed 
in a rat model that MWCNT labeled cells can be transplanted and easily controlled and 
localized in the target site using low intensity magnetic fields. Therefore, this approach 
could be used to allow site-specific, guided localization of human islet grafts containing 
MWCNTs, which is of potential interest in pre-clinical and clinical islet transplantation, in 
particular when the implantation is performed at specific sites, such as subcutaneous or 
intramuscular spaces.  
Altogether, the work presented in this thesis provides several evidences of how specific 
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nanomedicine tools can be usefully applied in the field of islet transplantation, possibly 
contributing to make this procedure a safer and more effective strategy for the cure of 
type 1 diabetes.  
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